Clover Health Investments (CLOV) CLO Soares Sells $69K of Stock
Key Points
- Clover Health Investments, Corp. Chief Legal Officer Karen Soares sold 14,673 shares on October 15, 2026, for about $68,669 under a pre-arranged plan.
- After the trade, Karen Soares holds 1,592,698 $CLOV shares, down 0.91% from before the trade.
- The stock traded around $4.44 recently, down about 5.1% from its close on the transaction date.
- Institutional investors like Nuveen, LLC and PNC Financial Services Group, Inc. adjusted their holdings earlier in the year.
Since the trade, $CLOV is down 5.1% to date (from the $4.68 close on Oct 15, 2026).
Get Clover Health Investments, Corp. text alerts
We text you when insiders, Congress, analysts or big funds move on $CLOV.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Clover Health Investments, Corp. alert may contain errors. Disclosures
Karen Soares, Chief Legal Officer at Clover Health Investments, Corp., sold 14,673 shares of company stock on October 15, 2026. According to a Form 4 filing with the SEC, the shares were disposed of at a price of $4.68 each, for a total value of about $68,669. The sale was carried out under a pre-arranged trading plan.
CLOV
Clover Health Investments, Corp.
Inside Karen Soares's Clover Health Trade
The planned transaction trimmed the Chief Legal Officer's holdings by about 0.91%. Following the trade, Soares directly owned 1,592,698 shares of the healthcare company. The stock closed at $4.68 on the day of the transaction.
Other Institutional Activity in Clover Health
Other institutional players adjusted their positions in the healthcare provider earlier. Nuveen, LLC grew its holdings by 5,356,158 shares, ending with 6,291,699 shares worth about $27,935,143. Meanwhile, PNC Financial Services Group, Inc. reduced its stake by 200,251 shares, leaving it with 3,563,874 shares valued at roughly $15,823,600.
Clover Health Investments, Corp. Stock Down 7.3%
The shares recently traded around $4.44 as of October 19, 2026, which is down about 5.1% from the close on the day of the insider trade. The stock sits roughly 20.6% below its 52-week high of $5.59 and about 181.0% above its 52-week low of $1.58. It is trading above its 200-day moving average of $3.42.
Recent Earnings
For the trailing twelve months, Clover Health posted revenue of $2,475,912,960 with negative earnings per share of $0.05. The company reported a net margin of -0.7% and a return on equity of -5.1%. Its next earnings report is expected on November 4, 2026.
Dividend
The company does not pay a dividend.
Insider Buying and Selling at Clover Health Investments, Corp.
Insider transactions included multiple planned sales earlier in the year, such as trades by CEO of Medicare Advantage Jamie Reynoso and Chief Legal Officer Karen Soares in June 2026.
Analysts Set New Price Targets
Canaccord Genuity maintained a Buy rating with a $5.50 target on July 21, 2026, while UBS kept a Neutral rating and set a $5.00 target on August 6, 2026. The stock carries a consensus mean target price of $5.38 across four analyst opinions.
About Clover Health
Headquartered in Wilmington, Delaware, Clover Health Investments, Corp. offers medicare advantage plans, including preferred provider organization and health maintenance organization options. The firm also provides Clover Assistant, a software tool designed to help physicians identify and manage chronic diseases.
Bottom Line
Investors are keeping an eye on upcoming filings and the company's next financial results scheduled for November 4, 2026. Pre-arranged sales by executives like Soares follow set schedules and provide insight into internal executive positioning.
Related Filing Alerts
Source: Karen Soares's Form 4 filing on $CLOV (Oct 15, 2026). Written by software, not financial advice. How we make alerts